mortality/aging
N |
• viable
|
• increased mortality after induction of SIRS (systemic inflammatory response syndrome) with injection of TNFA + Z-VAD-FMK (a caspase inhibitor)
• normal survival after induction of SIRS (systemic inflammatory response syndrome) with injection of TNFA + Z-VAD-FMK (a caspase inhibitor) when co-injected with RIPK1 inhibitor RIPA-56
|
growth/size/body
N |
• no gross dysmorphologies or defects
|